ClinicalTrials.gg
RecruitingNCT06330064Updated Oct 26, 2026

A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)

A Phase 1/2 interventional study of Ifinatamab deruxtecan in Recurrent or Metastatic Solid Tumors, sponsored by Daiichi Sankyo. Recruiting at 120 sites in 18 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-26.

Primary conditionnone(registry's first term: Recurrence)No conditionIs this wrong?Recurrence describes something many studies share rather than a condition a study is about. The study names no condition we can place it under, so it is not compared with other studies by condition.

Sponsored by Daiichi Sankyo · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started Apr 2024; still recruiting 2 years 7 months later.
Updated Oct 26, 20264 sites added4 sites removedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
680
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

This study is designed to assess the efficacy and safety of ifinatamab deruxtecan (I-DXD) in the following tumor types: endometrial cancer (EC); head and neck squamous cell carcinoma (HNSCC); pancreatic ductal adenocarcinoma (PDAC); colorectal cancer (CRC); hepatocellular carcinoma (HCC); adenocarcinoma of esophagus, gastroesophageal junction, and stomach (Ad-Eso/GEJ/gastric); urothelial carcinoma (UC); ovarian cancer (OVC); cervical cancer (CC); biliary tract cancer (BTC); human epidermal growth factor 2 (HER2)-low breast cancer (BC); HER2 immunohistochemistry (IHC) 0 BC; cutaneous melanoma; and neuroendocrine carcinoma (NEC).

Read the detailed description

This study will evaluate the efficacy and safety of I-DXd in participants with recurrent or metastatic solid tumors. The study will be divided into 3 parts: Stage 1, Stage 2 and an optional Stage 3. Each cohort starts with Stage 1 and may continue to Stage 2 if sufficient safety and efficacy data are observed. The EC cohort may proceed to an optional Stage 3 expansion based on the totality of available data.

The HCC Safety Run-In (Phase 1) will assess the safety and tolerability of I-DXd in participants with HCC.

02

Conditions studied

  • Recurrent or Metastatic Solid Tumors

Keywords

  • Recurrent or metastatic solid tumors
  • Endometrial cancer
  • Head and neck squamous cell carcinoma
  • Colorectal cancer
  • Hepatocellular carcinoma
  • Adenocarcinoma of esophagus, gastroesophageal junction, and stomach
  • Urothelial carcinoma
  • Ovarian cancer
  • Cervical cancer
  • Biliary tract cancer
  • Human epidermal growth factor 2 (HER2)-low breast cancer
  • HER2 immunohistochemistry 0 breast cancer
  • Cutaneous melanoma
  • Pancreatic ductal adenocarcinoma
  • Ifinatamab deruxtecan (I-DXD)
  • DS7300a
  • Neuroendocrine Carcinoma (NEC)
03

In context

Lead sponsor

Daiichi Sankyo is the lead sponsor of 322 studies on the registry; 37 are open to participants now.

Of its 51 completed or terminated interventional studies of FDA-regulated products, 38 (75%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Participants must meet all of the following criteria to be included in the study:

Common Inclusion Criteria for All Participants

  1. Participants must consent to provide a pretreatment tumor sample which has not been previously irradiated. Fresh are strongly preferred, however, if a fresh pretreatment biopsy is not feasible or the procedure is unsuccessful, an appropriate archival sample must be provided. The most recent archival sample obtained up to 5 years prior to consent is acceptable.
  2. Participants ages ≥18 years (follow local regulatory requirements if the legal age of consent for study participation is >18 years).
  3. At least 1 on computed tomography (CT) or magnetic resonance imaging (MRI) according to version 1.1 (RECIST v1.1), as assessed by the investigator.
  4. Documentation of radiological disease progression on or after the previous standard-of-care regimen. For NEC participants for which the standard therapy does not exist OR for which the standard therapy is not appropriate by the investigator: presence of advanced/ disease without previous regimen is acceptable.
  5. Has an (ECOG) performance status of 0 or 1.

Additional Inclusion Criteria for EC Participants

  1. or cytologically documented EC of any histological carcinoma subtype or endometrial carcinosarcoma, irrespective of microsatellite instability or mismatch repair status.
  2. Relapse or progression after a platinum-containing systemic treatment and an (ICI)-containing regimen (combined or sequential). Participants with actionable target tumor mutation should have been previously treated with targeted therapy, with a maximum of 3 for endometrial carcinoma or carcinosarcoma. /adjuvant therapy may count as 1 line of therapy if the subject progressed within 6 months after completion of therapy.

Additional Inclusion Criteria for HNSCC Participants

  1. Pathologically or cytologically documented unresectable or metastatic squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx, or larynx, excluding nasopharynx, nasal cavity and paranasal sinuses, and unknown primary.
  2. Has disease progression after platinum-based and ICI treatment, whether administered in combination or separately. Participants with actionable target tumor mutation should have been previously treated with targeted therapy, with a maximum of 2 prior therapy lines for unresectable or metastatic HNSCC.
  3. Participants without radiographic evidence of major blood vessel invasion/infiltration or tumor demonstrating a greater than (>)90-degree abutment or encasement of a major blood vessel.
  4. Participants with no prior history of Grade greater than or equal to (≥)3 bleeding as per the National Cancer Institute (NCI-CTCAE) v5.0 within 28 days prior to the start of study drug related to the current head and neck cancer may be included in the study.
  5. Documented p16 status for oropharyngeal cancer (historical results are acceptable if available).

Additional Inclusion Criterion for PDAC Participants

1. Pathologically or cytologically documented unresectable or metastatic pancreatic adenocarcinoma that has or progressed after 1 prior line of gemcitabine-based systemic therapy in the locally advanced/metastatic setting or after 2 lines of therapy if the participant has actionable target tumor mutation and has been previously treated with targeted therapy.

a. No prior treatment with topoisomerase I inhibitors, such as irinotecan or topotecan.

Additional Inclusion Criteria for CRC Participants

  1. Pathologically or cytologically documented unresectable or metastatic CRC with microsatellite stable status (MSS).
  2. Relapse or progression after 1 prior line of systemic therapy including a fluoropyrimidine plus oxaliplatin with or without anti-vascular endothelial growth factor (VEGF) monoclonal antibody (mAb) or anti-epidermal growth factor receptor mAb therapy, as clinically indicated, or relapse or progression after 2 lines of therapy if the subject has received targeted therapy.

    Note: Prior adjuvant/neoadjuvant systemic cytotoxic chemotherapy will count as 1 line of prior systemic therapy if there is documented disease progression during therapy or within 6 months of chemotherapy completion.

  3. No prior treatment with topoisomerase I inhibitors, such as irinotecan or topotecan.

Additional Inclusion Criteria for HCC Participants

  1. Pathologically or cytologically documented unresectable or metastatic HCC (fibrolamellar and mixed hepatocellular/cholangiocarcinoma subtypes are not eligible) or noninvasive diagnosis of HCC as per the American Association for the Study of Liver Diseases (AASLD) criteria in participants with a confirmed diagnosis of cirrhosis.
  2. Relapse or progression after 1 prior line of an ICI-containing regimen (combination or monotherapy) in the locally advanced/metastatic setting, or relapse or progression after 2 lines of therapy if the participant has an actionable target tumor mutation and has been treated with targeted therapy.
  3. Barcelona Clinic Liver Cancer (BCLC) Stage B or C.
  4. Liver function status should be (CP) Class A.
  5. Albumin- (ALBI) Grade 1 within 7 days prior to the first dose of study drug.
  6. Participants with large esophageal varices at risk of bleeding must be treated with conventional medical intervention: beta blockers or endoscopic treatment.

Additional Inclusion Criteria for Ad-eso/GEJ/Gastric Participants

  1. Pathologically or cytologically documented unresectable or metastatic Ad-eso/GEJ/Gastric that has relapsed or progressed after 1 prior line of systemic therapy in the locally advanced/metastatic setting.

    a. Participants with PD-(L)1+ or MSI-H/dMMR should receive ICI treatment if ICIs are standard of care in the country, unless the participant is ineligible for ICI treatment.

  2. If the participant has known history of positivity (defined by IHC 3+ or IHC 2+ and in situ hybridization [ISH] positive, as classified by American Society of Clinical Oncology - College of American Pathologists [ASCO CAP]) or actionable target, the participant must have been previously treated with a targeted therapy.

Additional Inclusion Criteria for UC Participants

  1. Pathologically or cytologically documented unresectable or metastatic UC of the bladder, renal pelvis, ureter, or urethra. Participants with histological variants are allowed if urothelial histology is predominant. Small cell/neuroendocrine tumors are not allowed even if mixed histology.
  2. Relapse or progression after at least 1 prior line of ICI-containing systemic therapy, and 1 prior line of systemic chemotherapy, given in combination with other anticancer therapy or separately, with a maximum of 3 prior therapy lines.

    1. At least 1 line of therapy should include enfortumab vedotin in countries where enfortumab vedotin is approved and available.
    2. Perioperative systemic therapies will be counted as 1 line of therapy.
    3. To meet inclusion criteria requirement of prior ICI-containing therapy, use in the perioperative or metastatic setting will suffice.
    4. Participants with actionable target tumor mutation should have been previously treated with targeted therapy.
    5. The same regimen administered twice in different disease settings will be counted as 1 line of prior therapy.

Additional Inclusion Criteria for CC Participants

  1. Histologically confirmed unresectable or metastatic CC that was previously treated with ≥1 prior line of systemic therapy in the locally advanced or metastatic setting. Participants with actionable target tumor mutation should have been previously treated with targeted therapy.
  2. Participants should receive prior anti-programmed death 1 (PD-1)//programmed death-ligand 1 (PD-L1) treatment and/or tisotumab vedotin if those are standard of care in the country, unless the participant is ineligible for these treatments.

Additional Inclusion Criteria for OVC Participants

  1. Histologically confirmed high-grade serous OVC, high-grade endometrioid OVC, primary peritoneal cancer, or fallopian tube cancer that was previously treated with at least 1 line of platinum-based therapy and bevacizumab unless the participant is ineligible for treatment with bevacizumab.
  2. Participant is no longer considered eligible for platinum-based therapy per the investigator's opinion or has progressed less than 180 days after the last dose of platinum therapy.
  3. Participant is not considered primary platinum refractory and has not progressed during platinum treatment or within 4 weeks after the completion of platinum treatment.
  4. Participants with actionable target tumor mutation should have been previously treated with targeted therapy.

Additional Inclusion Criteria for BTC Participants

  1. Pathologically or cytologically documented unresectable or metastatic BTC (intra- or extrahepatic cholangiocarcinoma or gallbladder carcinoma).
  2. Relapse or progression after at least 1 prior line of systemic therapy, or 2 prior lines of systemic therapy if the participant has an actionable target and has received targeted therapy.
  3. Histological subtypes other than ampullary cancer, small cell cancer, lymphoma, sarcoma, neuroendocrine tumors, mixed tumor histology, and/or mucinous cystic neoplasms (Please note that the histological subtypes listed here are not allowed.)

Additional Inclusion Criteria for HER2-Low BC Participants

  1. Pathologically or cytologically documented unresectable or metastatic BC.
  2. Low HER2 expression, defined as IHC 2+/ISH- or IHC 1+ (ISH- or untested), according to ASCO-CAP 2018 HER2 testing guidelines, based on most recent testing, regardless of hormonal status.
  3. Progression on or after treatment with trastuzumab deruxtecan (T-DXd).
  4. Relapse or progression after at least 2 and a maximum of 3 prior lines of systemic therapy. Participants with metastatic hormone receptor (HR)+ BC who have received endocrine-based therapy and have received at least 2 and a maximum of 3 prior lines of additional systemic therapy in the metastatic setting. Participants with actionable target tumor mutation should have been previously treated with targeted therapy.

Additional Inclusion Criteria for HER2 IHC 0 BC Participants

  1. Pathologically or cytologically documented unresectable or metastatic BC.
  2. Negative for HER2 expression, defined as IHC 0 (ISH- or untested) according to ASCO-CAP 2018 HER2 testing guidelines, based on the most recent testing, regardless of hormonal status.
  3. Relapse or progression after at least 2 and a maximum of 3 prior lines of systemic therapy. Participants with metastatic HR+ BC who have received endocrine-based therapy and have received at least 2 and a maximum of 3 prior lines of additional systemic therapy in the metastatic setting. Participants with actionable target tumor mutation should have been previously treated with targeted therapy.

Additional Inclusion Criteria for Cutaneous (Acral and Non-acral) Melanoma Participants

  1. Histologically or cytologically confirmed cutaneous (acral and non-acral) melanoma.
  2. Disease progression while on or after having received treatment with ≥1 prior line of ICI based therapy. Prior anti-PD-(L)1 therapy in the adjuvant setting may be counted as 1 line if there is recurrence within 12 weeks of the last dose. If the subject had BRAF mutated melanoma or other actionable target tumor mutation, they must have had disease progression on targeted therapy as well.

Additional Inclusion Criteria for NEC Participants

  1. Histologically or cytologically confirmed NEC types other than neuroendocrine prostate cancer (NEPC), small cell lung cancer (SCLC), and Merkel Cell Carcinoma, as defined by WHO 2022. Participants must meet at least 1 of the following criteria:

    1. Disease that is relapsed/refractory to standard systemic therapy OR
    2. Disease for which standard therapy does not exist OR
    3. Disease for which standard therapy is not considered appropriate by the investigator.
  2. Participants with mixed histology of large-cell neuroendocrine carcinoma (LCNEC) and SCLC are eligible if the neuroendocrine component predominates and represents at least 50% of the overall tumor tissue.

Exclusion Criteria:

Participants who meet any of the following criteria will be disqualified from entering the study:

  1. Prior treatment with orlotamab, enoblituzumab, or other B7-homologue 3 (B7-H3)-targeted agents, including I-DXd.
  2. Prior discontinuation of an antibody drug conjugate (ADC) that consists of an exatecan derivative (e.g., T-DXd) due to treatment-related toxicities.
  3. Clinically active , spinal cord compression, or , defined as untreated or symptomatic, or requiring therapy with or anticonvulsants to control associated symptoms.
  4. Inadequate treatment before enrollment as specified in the protocol.
  5. Any history of interstitial lung disease (ILD)/pneumonitis, current ILD, or suspicion of ILD.
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
680 participants (estimated)

Study arms

  • Experimental
    Cohort 1: Endometrial Cancer (EC)

    Participants with recurrent or metastatic EC who were previously treated with 1 or more systemic therapy will receive I-DXd, 12 milligrams per kilogram (mg/kg), intravenous (IV) infusion.

    Drug: Ifinatamab deruxtecan

  • Experimental
    Cohort 2: Head and Neck Squamous Cell Carcinoma (HNSCC)

    Participants with recurrent or metastatic HNSCC who were previously treated with 1 or more systemic therapy will receive I-DXd, 12 mg/kg, IV infusion.

    Drug: Ifinatamab deruxtecan

  • Experimental
    Cohort 3: Pancreatic Ductal Adenocarcinoma (PDAC)

    Participants with recurrent or metastatic PDAC who were previously treated with 1 or more systemic therapy will receive I-DXd, 12 mg/kg, IV infusion.

    Drug: Ifinatamab deruxtecan

  • Experimental
    Cohort 4: Colorectal Cancer (CRC)

    Participants with recurrent or metastatic CRC who were previously treated with 1 or more systemic therapy will receive I-DXd, 12 mg/kg, IV infusion.

    Drug: Ifinatamab deruxtecan

  • Experimental
    Cohort 5: Hepatocellular Carcinoma (HCC)

    Participants with recurrent or metastatic HCC who were previously treated with 1 or more systemic therapy will receive I-DXd, at the determined dose.

    Drug: Ifinatamab deruxtecan

  • Experimental
    Cohort 6: Adenocarcinoma of esophagus, gastroesophageal junction, and stomach (Ad-Eso/GEJ/gastric)

    Participants with recurrent or metastatic Ad-Eso/GEJ/gastric who were previously treated with 1 or more systemic therapy will receive I-DXd, 12 mg/kg, IV infusion.

    Drug: Ifinatamab deruxtecan

  • Experimental
    Cohort 7: Urothelial Carcinoma (UC)

    Participants with recurrent or metastatic UC who were previously treated with 1 or more systemic therapy will receive I-DXd, 12 mg/kg, IV infusion.

    Drug: Ifinatamab deruxtecan

  • Experimental
    Cohort 8: Ovarian Cancer (OVC)

    Participants with recurrent or metastatic non-squamous OVC who were previously treated with 1 or more systemic therapy will receive I-DXd, 12 mg/kg, IV infusion.

    Drug: Ifinatamab deruxtecan

  • Experimental
    Cohort 9: Cervical Cancer (CC)

    Participants with recurrent or metastatic CC who were previously treated with 1 or more systemic therapy will receive I-DXd, 12 mg/kg, IV infusion.

    Drug: Ifinatamab deruxtecan

  • Experimental
    Cohort 10: Biliary Tract Cancer (BTC)

    Participants with recurrent or metastatic BTC who were previously treated with 1 or more systemic therapy will receive I-DXd, 12 mg/kg, IV infusion.

    Drug: Ifinatamab deruxtecan

  • Experimental
    Cohort 11: Human epidermal growth factor 2 (HER2)-low breast cancer (BC)

    Participants with recurrent or metastatic human epidermal growth factor 2 (HER2)-low BC who were previously treated with 1 or more systemic therapy will receive I-DXd, 12 mg/kg, IV infusion.

    Drug: Ifinatamab deruxtecan

  • Experimental
    Cohort 12: HER2 Immunohistochemistry (IHC) 0 BC

    Participants with recurrent or metastatic HER2 IHC 0 BC who were previously treated with 1 or more systemic therapy will receive I-DXd, 12 mg/kg, IV infusion.

    Drug: Ifinatamab deruxtecan

  • Experimental
    Cohort 13: Cutaneous Melanoma

    Participants with recurrent or metastatic cutaneous melanoma who were previously treated with 1 or more systemic therapy will receive I-DXd, 12 mg/kg, IV infusion.

    Drug: Ifinatamab deruxtecan

  • Experimental
    Cohort 14: Neuroendocrine Carcinoma (NEC)

    Participants with recurrent or metastatic NEC who were previously treated with 1 or more systemic therapy or for whom the standard therapy is not considered appropriate by the investigator will receive I-DXd, 12 mg/kg, IV infusion.

    Drug: Ifinatamab deruxtecan

Interventions

06

What researchers measure

Primary outcomes

  1. Objective Response Rate (ORR) as Assessed by Investigator

    ORR is defined as the percentage of participants with a best overall response (BOR) of confirmed complete response (CR) or confirmed partial response (PR) as assessed by Investigator per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.

    Time frame: From the time of the first dose of study drug until the date of documented disease progression, death, loss to follow-up, or withdrawal by the subject, whichever occurs first (up to approximately 60 months)

  2. Number of Participants Reporting Dose-limiting Toxicities (DLTs) in the HCC Cohort

    A DLT is defined as any treatment-emergent adverse event (TEAE) not attributable to disease or disease-related processes that occurs during the DLT evaluation period (from C1D1 to the end of Cycle 1 in Safety Run-in) and is Grade 3 or above, according to NCI-CTCAE version 5.0, with the exceptions as noted in the protocol.

    Time frame: Cycle 1 Day 1 to Cycle 1 Day 21

  3. Number of Participants Reporting TEAEs and Death in the HCC Cohort

    An adverse event (AE) is any untoward medical occurrence in a participant administered a pharmaceutical product and that does not necessarily have to have a causal relationship with this treatment. TEAEs are defined as those AEs with start or worsening after the first dose date of I-DXd and up to 40 (+7) days after the last dose date of study drug.

    Time frame: From date of signing the informed consent form up to 47 days after the last dose of study drug, up to approximately 60 months

Secondary outcomes

  1. Incidence of Treatment Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), and Adverse Events of Special Interest (AESIs)

    An adverse event (AE) is any untoward medical occurrence in a participant administered a pharmaceutical product and that does not necessarily have to have a causal relationship with this treatment. TEAEs are defined as those AEs with start or worsening after the first dose date of I-DXd and up to 40 (+7) days after the last dose date of study drug. A serious AE is defined as any untoward medical occurrence that at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, is an important medical event, or may jeopardize the participant or may require medical or surgical intervention to prevent one of the other outcomes noted. AESIs will also be assessed. AEs will be coded using MedDRA and will be graded using NCI-CTCAE v5.0.

    Time frame: From date of signing the informed consent form up to 47 days after the last dose of study drug, up to approximately 60 months

  2. Duration of Response (DoR)

    DoR is defined as the time from the date of first documentation of objective tumor response (complete response \[CR\] or partial response \[PR\]) to the first documentation of objective tumor progression or death due to any cause, whichever occurs first, as assessed by the Investigator per RECIST v1.1, respectively. CR is defined as a disappearance of all target and non-target lesions and PR is defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.

    Time frame: From the time of the first dose of study drug until the date of documented disease progression, death, loss to follow-up, or withdrawal by the subject, whichever occurs first, up to approximately 60 months

  3. Progression-free Survival (PFS)

    PFS is defined as the time interval from the date of the first dose of study drug to the date of disease progression as assessed by the investigator per RECIST v1.1 or death from any cause.

    Time frame: From the time of the first dose of study drug until the date of documented disease progression, death, loss to follow-up, or withdrawal by the subject, whichever occurs first, up to approximately 60 months

  4. Disease Control Rate (DCR)

    DCR is defined as the percentage of participants who achieved a BOR of confirmed CR, confirmed PR, or stable disease (SD) as assessed by the Investigator per RECIST v1.1, respectively. CR is defined as a disappearance of all target and non-target lesions, PR is defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters and stable disease (SD) is defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD). PD is defined as at least a 20% increase in the sum of diameters of target lesions.

    Time frame: From the time of the first dose of study drug until the date of documented disease progression (by investigator), death, loss to follow-up, or withdrawal by the subject, whichever occurs first, up to approximately 60 months

  5. Overall Survival (OS)

    OS is defined as the time interval from the date of the first dose of study drug to the date of death from any cause.

    Time frame: From the date of the first dose of drug up to the date of death due to any cause, up to approximately 60 months

  6. Pharmacokinetic Parameter Maximum Concentration (CMax) for I DXd, total anti-B7-H3 antibody, and DXd

    Plasma pharmacokinetic parameters will be estimated using noncompartmental methods.

    Time frame: Cycles1 & 3 Day1:pre-dose,end of infusion(EOI),post-dose at 3 hours(hr),6 hr;24 hr,168 hr;336 hr;504 hr; Cycles 2, 4, and 5 Day 1:pre-dose and EOI;Cycle 7 and every 2 cycles thereafter up to end of study(EOS)(60 months):pre-dose(every cycle is 21 days)]

  7. Pharmacokinetic Parameter Time to Reach Maximum Plasma Concentration (TMax) for I DXd, total anti-B7-H3 antibody, and DXd

    Plasma pharmacokinetic parameters will be estimated using noncompartmental methods.

    Time frame: Cycles 1 and 3 Day 1: pre-dose, EOI, 3 hr, 6 hr; 24 hr, 168 hr; 336 hr; 504 hr; Cycles 2, 4, and 5 Day 1: pre-dose and EOI; Cycle 7 and every 2 cycles thereafter up to EOS (60 months): pre-dose (every cycle is 21 days)]

  8. Pharmacokinetic Parameter Half-life (t1/2) for I DXd, total anti-B7-H3 antibody, and DXd

    Plasma pharmacokinetic parameters will be estimated using noncompartmental methods.

    Time frame: Cycles 1 and 3 Day 1: pre-dose, EOI, 3 hr, 6 hr; 24 hr, 168 hr; 336 hr; 504 hr; Cycles 2, 4, and 5 Day 1: pre-dose and EOI; Cycle 7 and every 2 cycles thereafter up to EOS (60 months): pre-dose (every cycle is 21 days)]

  9. Pharmacokinetic Parameter Minimum Concentration (Ctrough) for I DXd, total anti-B7-H3 antibody, and DXd

    Plasma pharmacokinetic parameters will be estimated using noncompartmental methods.

    Time frame: Cycles 1 and 3 Day 1: pre-dose, EOI, 3 hr, 6 hr; 24 hr, 168 hr; 336 hr; 504 hr; Cycles 2, 4, and 5 Day 1: pre-dose and EOI; Cycle 7 and every 2 cycles thereafter up to EOS (60 months): pre-dose (every cycle is 21 days)]

  10. Pharmacokinetic Parameter Area Under the Curve (AUC) for I DXd, total anti-B7-H3 antibody, and DXd

    Plasma pharmacokinetic parameters will be estimated using noncompartmental methods.

    Time frame: Cycles 1 and 3 Day 1: pre-dose, EOI, 3 hr, 6 hr; 24 hr, 168 hr; 336 hr; 504 hr; Cycles 2, 4, and 5 Day 1: pre-dose and EOI; Cycle 7 and every 2 cycles thereafter up to EOS (60 months): pre-dose (every cycle is 21 days)]

  11. Percentage of Participants Who Are Anti-Drug Antibody (ADA)-Positive (Baseline and Post-Baseline)

    Anti-drug antibodies will be measured in plasma using a validated assay.

    Time frame: Baseline up to 60 months

  12. Percentage of Participants Who Have Treatment-emergent ADA

    Anti-drug antibodies will be measured in plasma using a validated assay.

    Time frame: Baseline up to 60 months

07

Study locations

104 of 120 sites recruiting
  • Valkyrie Clinical Trials
    Los Angeles, California 90067, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Los Angeles Cancer Network
    Los Angeles, California 91204, United States
    Recruiting
    • Principal Investigator · Contact
  • Pih Health Hematology Medical Oncology
    Whittier, California 90602, United States
    Recruiting
    • Principal Investigator · Contact
  • Orchard Healthcare Research Inc
    Skokie, Illinois 60077, United States
    Recruiting
    • Principal Investigator · Contact
  • M Health Fairview University of Minnesota Medical Center
    Minneapolis, Minnesota 55114, United States
    Recruiting
    • Principal Investigator · Contact
  • NYU Langone Health
    New York, New York 10016, United States
    Recruiting
    • Principal Investigator · Contact
  • Icahn School of Medicine At Mount Sinai Prime
    New York, New York 10029, United States
    Recruiting
    • Principal Investigator · Contact
  • Clinical Research Alliance, Inc
    Westbury, New York 11590, United States
    Recruiting
    • Principal Investigator · Contact
  • White Plains Hospital
    White Plains, New York 10601, United States
    Recruiting
    • Principal Investigator · Contact
  • Erlanger Health, Inc
    Chattanooga, Tennessee 37403, United States
    Recruiting
    • Principal Investigator · Contact
  • The West Clinic
    Germantown, Tennessee 38138, United States
    Recruiting
    • Principal Investigator · Contact
  • SCRI Oncology Partners
    Nashville, Tennessee 37203, United States
    Recruiting
  • Texas Oncology - West Texas
    Amarillo, Texas 79124, United States
    Recruiting
  • Texas Oncology, P.A.
    Dallas, Texas 75246, United States
    Recruiting
  • Texas Oncology Gulf Coast
    Pearland, Texas 77584, United States
    Recruiting
  • Huntsman Cancer Institute, University of Utah
    Salt Lake City, Utah 84112, United States
    Recruiting
    • Principal Investigator · Contact
  • Virginia Cancer Specialists
    Fairfax, Virginia 22031, United States
    Recruiting
    • Principal Investigator · Contact
  • Wenatchee Valley Hospital and Clinics
    Wenatchee, Washington 98801, United States
    Recruiting
    • Principal Investigator · Contact
  • Centro de Investigaciones Medicas Mar Del Plata
    Mar del Plata, Buenos Aires B7600FYK, Argentina
    Recruiting
    • Principal Investigator · Contact
  • Hospital Aleman
    Buenos Aires, Ciudad Autonoma Buenos Aires C1118AAT, Argentina
    Recruiting
    • Principal Investigator · Contact
  • Hospital Sirio Libanes
    Caba, Ciudad Autonoma Buenos Aires C1419GEP, Argentina
    Recruiting
    • Principal Investigator · Contact
  • DIABAID
    Buenos Aires, C1061ABD, Argentina
    Not yet recruiting
    • Principal Investigator · Contact
  • Centro Médico Austral
    Ciudad Autonoma Buenos Aires, 1019, Argentina
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Centro de Investigaciones Medicas y Desarrollo LC SRL LC Investigacion
    Ciudad Autonoma Buenos Aires, C1113AAE, Argentina
    Recruiting
    • Principal Investigator · Contact
  • Blacktown Hospital
    Blacktown, New South Wales NSW 2148, Australia
    Recruiting
    • Principal Investigator · Contact
  • St Vincent'S Hospital Sydney
    Mount Kuring-Gai, New South Wales 2080, Australia
    Recruiting
    • Principal Investigator · Contact
  • Genesiscare North Shore Oncology
    St Leonards, New South Wales 2065, Australia
    Recruiting
    • Principal Investigator · Contact
  • Princess Alexandra Hospital
    Woolloongabba, Queensland 4102, Australia
    Recruiting
    • Principal Investigator · Contact
  • St John of God Subiaco Hospital
    Subiaco, Western Australia 6008, Australia
    Recruiting
    • Principal Investigator · Contact
  • Cliniques Universitaires Saint-Luc
    Brussels, 1200, Belgium
    Recruiting
    • Principal Investigator · Contact
  • Grand Hospital de Charleroi
    Charleroi, 6000, Belgium
    Recruiting
    • Principal Investigator · Contact
  • Universitair Ziekenhuis Gent
    Ghent, 9000, Belgium
    Not yet recruiting
    • Principal Investigator · Contact
  • Uz Leuven
    Leuven, 3000, Belgium
    Recruiting
    • Principal Investigator · Contact
  • Chu de Liă Ge
    Liège, 4000, Belgium
    Not yet recruiting
    • Principal Investigator · Contact
  • Hospital de Clínicas de Porto Alegre
    Porto Alegre, Rio Grande do Sul 90035-903, Brazil
    Recruiting
    • Principal Investigator · Contact
  • Hospital São Lucas Da Pucrs
    Porto Alegre, Rio Grande do Sul 90610-000, Brazil
    Recruiting
    • Principal Investigator · Contact
  • Cepon - Centro de Pesquisas Oncolă"Gicas de Santa Catarina
    Florianópolis, Santa Catarina 88034-000, Brazil
    Recruiting
    • Principal Investigator · Contact
  • Hospital de Câncer de Barretos - Fundação Pio XII
    Barretos, São Paulo 14784-400, Brazil
    Recruiting
    • Principal Investigator · Contact
  • Centro de Pesquisas Clinicas da Fundação Doutor Amaral Carvalho
    Jaú, São Paulo 17210-120, Brazil
    Recruiting
    • Principal Investigator · Contact
  • Biocenter
    Concepción, Biobio 4030000, Chile
    Recruiting
    • Principal Investigator · Contact
  • Centro Del Cancer UC
    Santiago, Santiago Metropolitan 8320000, Chile
    Recruiting
    • Principal Investigator · Contact
  • Clinica Redsalud Vitacura
    Santiago, Santiago Metropolitan 8320000, Chile
    Recruiting
    • Principal Investigator · Contact
  • Ic La Serena Research
    La Serena, 1720430, Chile
    Not yet recruiting
    • Principal Investigator · Contact
  • James Lind Centro de Investigacion Del Cancer
    Temuco, 4800827, Chile
    Not yet recruiting
    • Principal Investigator · Contact
  • Centre Georges François Leclerc
    Dijon, Cote dÝOr 21000, France
    Recruiting
    • Principal Investigator · Contact
  • Hopital Saint Andre
    Bordeaux, Gironde 33075, France
    Recruiting
    • Principal Investigator · Contact
  • Institut Bergonié
    Bordeaux, Gironde 33076, France
    Recruiting
    • Principal Investigator · Contact
  • Institut Régional Du Cancer de Montpellier
    Montpellier, Herault 34298, France
    Recruiting
    • Principal Investigator · Contact
  • CRLCC Eugene Marquis
    Rennes, Ille Et Vilaine 35042, France
    Recruiting
    • Principal Investigator · Contact
  • Ico - Site René Gauducheau
    Saint-Herblain, Loire Atlantique 44800, France
    Recruiting
    • Principal Investigator · Contact
  • Institut Curie - Site de Paris
    Paris, Paris 75005, France
    Recruiting
    • Principal Investigator · Contact
  • Centre Léon Bérard
    Lyon, Rhone 69008, France
    Recruiting
    • Principal Investigator · Contact
  • GustaveRoussy DptPharmacie
    Villejuif, Val De Marne 94805, France
    Recruiting
    • Principal Investigator · Contact
  • Chu Besançon - Hôpital Jean Minjoz
    Besançon, 25000, France
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Institut Claudius Regaud
    Toulouse, 31059, France
    Not yet recruiting
    • Principal Investigator · Contact
  • Universitaetsklinikum Heidelberg
    Heidelberg, Baden-Wurttemberg 69120, Germany
    Recruiting
    • Principal Investigator · Contact
  • Slk-Kliniken Heilbronn Gmbh
    Heilbronn, Baden-Wurttemberg 74078, Germany
    Recruiting
    • Principal Investigator · Contact
  • Universitätsklinikum Münster, Medizinische Klinik A
    Münster, North Rhine-Westphalia 48149, Germany
    Recruiting
    • Principal Investigator · Contact
  • Univ der Johannes GutenbergU
    Mainz, Rhineland-Palatinate 55131, Germany
    Recruiting
    • Principal Investigator · Contact
  • Staedtisches Klinikum Dresden Standort Dresden-Friedrichstadt
    Dresden, Saxony 01067, Germany
    Recruiting
    • Principal Investigator · Contact
  • Universitäres Krebszentrum Leipzig UCCL, UKL AöR
    Leipzig, Saxony 04103, Germany
    Recruiting
    • Principal Investigator · Contact
  • Vivantes Klinikum Neukoelln
    Berlin, 12351, Germany
    Recruiting
    • Principal Investigator · Contact
  • Charită - Campus Charită Mitte
    Berlin, 13353, Germany
    Recruiting
    • Principal Investigator · Contact
  • St Vincent'S University Hospital
    Dublin, Dublin D04 T6F4, Ireland
    Recruiting
    • Principal Investigator · Contact
  • Cork University Hospital
    Cork, T12DC4A, Ireland
    Not yet recruiting
    • Principal Investigator · Contact
  • Mater Misericordiae University Hospital
    Dublin, D07 R2WY, Ireland
    Recruiting
    • Principal Investigator · Contact
  • Tallaght University Hospital
    Dublin, D24 NR0A, Ireland
    Recruiting
    • Principal Investigator · Contact
  • University Hospital Galway
    Galway, H91YR71, Ireland
    Not yet recruiting
    • Principal Investigator · Contact
  • Fondazione Del Piemonte Per L'Oncologia Irccs Candiolo
    Candiolo, 10060, Italy
    Recruiting
    • Principal Investigator · Contact
  • Fondazione IRCCS Istituto Nazionale dei Tumori
    Milan, 20133, Italy
    Recruiting
    • Principal Investigator · Contact
  • Azienda Socio Sanitaria Territoriale Niguarda (Grande Ospedale Metropolitano Niguarda)
    Milan, 20162, Italy
    Recruiting
    • Principal Investigator · Contact
  • Istituto Nazionale Tumori Fondazione G. Pascale
    Naples, 80131, Italy
    Recruiting
    • Principal Investigator · Contact
  • Fondazione Policlinico Universitario Agostino Gemelli IRCCS
    Rome, 00168, Italy
    Recruiting
    • Principal Investigator · Contact
  • Istituto Clinico Humanitas
    Rozzano, 20089, Italy
    Recruiting
    • Principal Investigator · Contact
  • Aichi Cancer Center Hospital
    Nagoya, Aichi-ken 464-8681, Japan
    Recruiting
    • Principal Investigator · Contact
  • National Cancer Center Hospital East
    Kashiwa, Chiba 277-8577, Japan
    Recruiting
    • Principal Investigator · Contact
  • National Hospital Organization Shikoku Cancer Center
    Matsuyama, Ehime 791-0280, Japan
    Recruiting
    • Principal Investigator · Contact
  • Kindai University Hospital
    Ōsaka-sayama, Osaka 589-8511, Japan
    Recruiting
    • Principal Investigator · Contact
  • Shizuoka Cancer Center
    Nagaizumi-cho, Shizuoka 411-8777, Japan
    Recruiting
    • Principal Investigator · Contact
  • National Cancer Center Hospital
    Chuo-ku, Tokyo 104-0045, Japan
    Recruiting
    • Principal Investigator · Contact
  • The Cancer Institute Hospital of Jfcr
    Koto-ku, Tokyo 135-8550, Japan
    Recruiting
    • Principal Investigator · Contact
  • Saitama Cancer Center
    Saitama, 362-0806, Japan
    Recruiting
    • Principal Investigator · Contact
  • Medical Care & Research Sa de Cv
    Mérida, 97070, Mexico
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Centro de Atenciă"N E Investigaciă"N Clă Nica En Oncologă A
    Mérida, 97134, Mexico
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Cryptex Investigacion Clinica S.A. de C.V.
    México, 06100, Mexico
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Amsterdam Umc, Locatie Vumc
    Amsterdam, 1081 HV, Netherlands
    Recruiting
    • Principal Investigator · Contact
  • Universitair Medisch Centrum Groningen
    Groningen, 9713 GZ, Netherlands
    Recruiting
    • Principal Investigator · Contact
  • Radboudumc Nijmegen
    Nijmegen, 6525 GA, Netherlands
    Recruiting
    • Principal Investigator · Contact
  • Erasmus Medisch Centrum
    Rotterdam, 3015 GD, Netherlands
    Recruiting
    • Principal Investigator · Contact
  • Umc Utrecht
    Utrecht, 3584 CW, Netherlands
    Recruiting
    • Principal Investigator · Contact
  • SPZOZ Szpital Uniwer w Krakowie
    Krakow, 30-688, Poland
    Recruiting
    • Principal Investigator · Contact
  • Instytut MSF Sp. z o.o.
    Lodz, 90-302, Poland
    Recruiting
    • Principal Investigator · Contact
  • MRUK-MED i Spółka z ograniczoną odpowiedzialnością
    Rzeszów, 35-021, Poland
    Recruiting
    • Principal Investigator · Contact
  • Mazowiecki Szpital Wojewodzki W Siedlcach Sp Z O O
    Siedlce, 08-110, Poland
    Recruiting
    • Principal Investigator · Contact
  • Aidport Sp Z O.O.
    Skorzewo, 60-185, Poland
    Recruiting
    • Principal Investigator · Contact
  • Instituto Portuguă S de Oncologia de Lisboa Francisco Gentil, Epe
    Lisbon, 1099-023, Portugal
    Recruiting
    • Principal Investigator · Contact
  • Fundação Champalimaud
    Lisbon, 1400-038, Portugal
    Recruiting
    • Principal Investigator · Contact
  • Centro Hospitalar Universitário de Lisboa Norte
    Lisbon, 1649-035, Portugal
    Recruiting
    • Principal Investigator · Contact
  • Centro Hospitalar Universitario de Santo Antonio
    Porto, 4099-001, Portugal
    Recruiting
    • Principal Investigator · Contact
  • Inst Portude Onco do Porto
    Porto, 4200-072, Portugal
    Recruiting
    • Principal Investigator · Contact

Showing the first 100 of 120 sites across 18 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes — De-identified individual participant data (IPD) on completed studies and applicable supporting clinical trial documents may be available upon request at https://vivli.org/. In cases where clinical trial data and supporting documents are provided pursuant to our company policies and procedures, Daiichi Sankyo will continue to protect the privacy of our clinical trial participants. Details on data sharing criteria and the procedure for requesting access can be found at this web address: https://vivli.org/ourmember/daiichi-sankyo/

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: Completed studies that has reached a global end or completion with all data set collected and analyzed, and for which the medicine and indication have received European Union (EU) and United States (US), and/or Japan (JP) marketing approval on or after 01 January 2014 or by the US or EU or JP Health Authorities when regulatory submissions in all regions are not planned and after the primary study results have been accepted for publication.

Access criteria: Formal request from qualified scientific and medical researchers on IPD and clinical study documents on completed clinical trials supporting products submitted and licensed in the United States, the European Union and/or Japan from 01 January 2014 and beyond for the purpose of conducting legitimate research. This must be consistent with the principle of safeguarding study participants' privacy and consistent with provision of informed consent.

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Apr 2024 (actual). Primary completion is estimated for Jul 2028, 51 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 19, 2024
First posted
Mar 26, 2024
StartActual
Apr 10, 2024
Primary completionEst.
Jul 25, 2028
CompletionEst.
Jul 25, 2028
Last update
Oct 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
4 sites added, 4 sites removed
Show 4 added (1 Belgium, 1 Brazil, 1 Mexico, 1 Portugal)
  • Chu de Liă Ge · Liège, Belgium
  • Cepon - Centro de Pesquisas Oncolă"Gicas de Santa Catarina · Florianópolis, Brazil
  • Centro de Atenciă"N E Investigaciă"N Clă Nica En Oncologă A · Mérida, Mexico
  • Instituto Portuguă S de Oncologia de Lisboa Francisco Gentil, Epe · Lisbon, Portugal
Show 4 removed
  • Chu de Liăge · Liège, Belgium
  • Cepon - Centro de Pesquisas Oncolăgicas de Santa Catarina · Florianópolis, Brazil
  • Centro de Atenciăn E Investigaciăn Clănica En Oncologăa · Mérida, Mexico
  • Instituto Portuguăs de Oncologia de Lisboa Francisco Gentil, Epe · Lisbon, Portugal
Oct 26, 2026
Show all 1 update
  1. Oct 26, 2026
    4 sites added, 4 sites removed
    Show 4 added (1 Belgium, 1 Brazil, 1 Mexico, 1 Portugal)
    • Chu de Liă Ge · Liège, Belgium
    • Cepon - Centro de Pesquisas Oncolă"Gicas de Santa Catarina · Florianópolis, Brazil
    • Centro de Atenciă"N E Investigaciă"N Clă Nica En Oncologă A · Mérida, Mexico
    • Instituto Portuguă S de Oncologia de Lisboa Francisco Gentil, Epe · Lisbon, Portugal
    Show 4 removed
    • Chu de Liăge · Liège, Belgium
    • Cepon - Centro de Pesquisas Oncolăgicas de Santa Catarina · Florianópolis, Brazil
    • Centro de Atenciăn E Investigaciăn Clănica En Oncologăa · Mérida, Mexico
    • Instituto Portuguăs de Oncologia de Lisboa Francisco Gentil, Epe · Lisbon, Portugal
    + 1 other change: identifiers

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06330064
Lead sponsor
Daiichi Sankyo
Responsible party
Sponsor
First posted
Mar 26, 2024
Start date
Apr 10, 2024
Primary completion
Jul 25, 2028 (estimated)
Completion
Jul 25, 2028 (estimated)
Last update
Oct 26, 2026

Study contacts

(US) Daiichi Sankyo Contact for Clinical Trial Information
Contact
CTRinfo@dsi.com
9089926400
(Asia) Daiichi Sankyo Contact for Clinical Trial Information
Contact
dsclinicaltrial@daiichisankyo.co.jp
+81-3-6225-1111 (M-F 9-5 JST

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ifinatamab deruxtecan

Start the discussion